Here’s What Pulled Down UnitedHealth (UNH) in Q2

Carillon Tower Advisers' Q2 2025 investor letter highlighted UnitedHealth Group (UNH), noting its nearly $112 billion in revenue, up 13% year-over-year. However, the fund expressed significant frustration over UNH's ability to forecast utilization, citing CEO Andrew Witty's exit, a second guidance suspension for 2025 due to accelerating Medicare costs, and a reported DOJ investigation into its Medicare Advantage business. Despite these challenges, Carillon maintains a tempered optimism, expecting UNH's 'short-cycle' insurance business to enable repricing for 2026 and a relatively swift recovery of lost 2025 earnings.

Analysis

UnitedHealth Group (UNH) is currently navigating significant operational and governance challenges that starkly contrast with its strong top-line performance. The company reported a 13% year-over-year revenue increase to nearly $112 billion in the second quarter of 2025, demonstrating fundamental business demand. However, this growth is overshadowed by severe internal issues, including the exit of CEO Andrew Witty and a second suspension of 2025 guidance due to an inability to forecast accelerating cost trends in its Medicare business. Compounding these issues are external pressures from a reported U.S. Department of Justice criminal investigation into its Medicare Advantage unit, which has contributed to the stock's 48.63% decline over the last 52 weeks. Despite these headwinds, Carillon Fund's management expresses a cautious long-term optimism, believing the short-cycle nature of the insurance business will allow UNH to reprice its offerings for 2026 and recover lost earnings. This potential turnaround is also reflected in institutional positioning, as the number of hedge fund portfolios holding the stock increased from 139 to 159 in the latest quarter.

Key Decisions for Investors

• Investors should closely monitor developments related to the DOJ investigation and the company's ability to issue stable 2026 guidance, as these are the primary risks clouding the stock's outlook.
• The core long-term investment thesis rests on management's ability to reprice its Medicare plans effectively for 2026 to recapture profitability, a scenario some institutional investors appear to be positioning for.
• Given the significant stock price decline amid strong revenue growth, current valuation may be attractive for a turnaround play, but this is contingent on the new leadership's capacity to resolve the forecasting and legal crises.